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Introduction
The primary goal of tumor, node and metastasis (TNM) 
classification is to provide a nomenclature for tumor extent 
that creates homogeneous cohorts of tumors. 
In the 7th Edition of the TNM classification for lung 
cancer there was some ambiguity about classification of 
multiple pulmonary sites. An international multidisciplinary 
subcommittee of the International Association for the Study 
of Lung Cancer (IASLC) Staging and Prognostic Factors 
committee (SPFC) has therefore proposed a revision of the 
classification of lung cancers with multiple pulmonary sites, 
according to the four following categories (1):
(I) Second primary lung cancers, indicating two 
different histologic types of malignant pulmonary 
lesions, synchronous or metachronous, to be staged 
separately, each with a T, N and M descriptor;
(II) Separate tumor nodules (intrapulmonary metastases), 
indicating a typical primary lung cancer, with one 
separate solid tumor nodule of the same histologic 
type. Based on the location of the second nodule 
relative to the primary tumor site, the tumor 
will be designated as: T3, in the same lobe; T4, 
in an ipsilateral but different lobe; M1a in the 
contralateral lung;
(III) Multifocal lung adenocarcinoma with ground 
glass/lepidic features, indicating multiple sub-solid 
nodules on CT examination. In this category, 
T should indicate the number of lesions, and a 
single N and M category applies to all tumor foci 
collectively;
(IV) Pneumonic-type of  lung adenocarcinoma, 
indicating a diffuse consolidative pattern without 
proximal bronchial obstruction.
The radiologist’s point of view
Changes in TNM staging for lung cancer have conditioned 
diagnosis and treatment of patients over time. For example, 
in 1993 the presence of multiple nodules used to raise the T 
category by one when in the same lobe while it raised T-staging 
to T4, when in a different lobe. In 2010 a separate nodule was 
classified as T3 for a same-lobe, T4 for an ipsilateral different-
lobe, and as M1a for a contralateral nodule. 
Since the stage of disease changes treatment, the radiologist 
should always be updated and aware of the latest version of 
TNM staging, in order not to incur in misleading reports.
Challenges for the radiologist at staging of lung carcinoma, 
are due to the overlap of appearances of different pulmonary 
nodules. Specifically, for the abovementioned four categories:
(I) Second primary lung cancers. The same CT 
appearance of different nodules does not establish 
by itself that the lesions are manifestations of the 
same tumor. Therefore, the maximum number of 
CT descriptors should be mentioned (2), in order 
to facilitate the discrimination of separate or single 
tumor source. In case of clear differences between 
nodules, these should be emphasized and the 
hypothesis of different primary tumors should be 
clearly stated in the report;
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(II) Separa te  tumor  nodules  ( in t rapulmonary 
metastases). Nodules may still be part of the same 
entity, even when they show different patterns 
of presentation. This may apply for example to 
nodules of different size, where necrotic changes 
and intratumoral heterogeneity may mimic different 
histologies. Moreover, according to different 
location and size of lesions (3,4), it is not always 
possible to biopsy all the nodules. In this specific 
setting, imaging examinations should indicate 
the highest number of descriptors of malignancy 
for each nodule, and emphasize similarities/
dissimilarities of nodules. Unfortunately, until 
more detailed studies of the tumoral texture will 
be recognized (5), the biopsy will remain the only 
method to assess different histologies;
(III) Multifocal lung adenocarcinoma with ground 
glass/lepidic features. The ground glass and solid 
components seen by CT generally correspond to 
lepidic and invasive histologic patterns, respectively. 
When reporting these lesions at CT, the lesion size 
should be given of both the largest diameter of the 
solid component and the entire lesion, comprising 
the ground-glass opacity. CT should also indicate 
the number of lesions;
(IV) Pneumonic-type of lung adenocarcinoma. Invasive 
mucinous adenocarcinoma shows a mixture 
of radiological features, corresponding to the 
underlying histological subtypes. These tumors 
typically present without nodal or systemic 
metastases despite diffuse pulmonary involvement 
and this may sometimes be a distinctive sign.
The thoracic surgeon’s point of view
Indications to curative lung cancer resection strictly relies 
on TNM staging and—following TNM modifications and 
updates—surgical indications to lung cancer treatments 
have been gradually modified and mainly expanded in the 
last years.
With the introduction of the abovementioned updates, 
surgery may play a more active role in lung cancer 
treatment, as following described:
(I) Second primary lung cancers. The new staging 
proposal—both in synchronous and metachronous 
cases—allows a local treatment that may be 
represented by a two-steps resection (in fit patients 
after an adequate cardiopulmonary assessment) 
or by combined surgical and stereotactic body 
radiation therapy (in patients with border line 
cardiopulmonary function) (6);
(II) Separate tumor nodules (intrapulmonary metastases). 
The presence of a second lesion in a different 
lobe, ipsilateral to a primary lung cancer that may 
be radically resected by standard lobectomy, may 
be treated with a subanatomic resection (e.g., 
wedge resection). Therefore this is not anymore 
a contraindication to surgery with radical intent. 
Moreover, the presence of additional lung nodule(s) 
in the same lobe can be radically treated by standard 
lobectomy (7);
(III) Multifocal lung adenocarcinoma with ground glass/
lepidic features. In this subset of patients, surgery 
may rarely play a curative role because of the 
multifocal spread of the tumor itself. Nevertheless, 
when a histological diagnosis is required, and 
bronchoscopy or CT-guided biopsy are not able to 
reach none of the target lesions, minimally invasive 
surgical approach may be advocated as a diagnostic 
tool. These lesions are very often difficult to locate 
at palpation, and preoperative localization by CT 
guided radioisotope injection is recommended (8);
(IV) Pneumonic-type of lung adenocarcinoma. In this 
subset of patients, surgery does not play any curative 
role; considering the local diffusion of the disease 
and the absence of distant and nodal involvement 
in this form, bilateral lung transplantation has 
been advocated in the past. However, due to high 
recurrence rate, transplantation for this indication 
remains controversial (9).
The oncologist’s point of view
The treatment of non-small cell lung cancer (NSCLC) has 
been changing dramatically in the last years, principally 
based on the identification of different genetic aberrations, 
as KRAS, EGFR and ALK, that present different incidence 
among different histological subtypes. Patients presenting 
druggable mutations as EGFR and ALK, show a significant 
improvement in survival, due to the utilization of first-, 
second- or third-generation of target agents. 
Although, the revision of TNM staging of lung cancers 
with multiple sites appears to have a limited significance 
for the oncological treatment, it may allow a better 
management of patients with multiple nodules:
(I) Second primary lung cancers. A multidisciplinary 
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approach is necessary to evaluate every different 
primary lung cancer. Generally, this pattern 
is characterized by different lung lesions with 
similar pathological features. A histopathological 
evaluation is mandatory on T and N components, 
where the two T evaluations differ. Evaluation of 
EGFR and ALK alterations should be considered in 
patients with lymph nodal involvement. However, 
in patients with two different primary lung cancers, 
with no lymph nodal involvement, there is no 
indication for induction chemotherapy;
(II) Separa te  tumor  nodules  ( in t rapulmonary 
metastases). NSCLC harboring EGFR mutations 
or ALK translocation frequently show as small lung 
nodules. In these cases, if possible, biomarkers 
analysis should be performed: in case of M1a 
disease positive to druggable mutations, target 
agents should be considered, especially if local 
treatment is not feasible;
(III) Multifocal lung adenocarcinoma with ground 
glass/lepidic features. Histopatologic evaluation 
o f  t h e s e  p u l m o n a r y  l e s i o n s  i s  e s s e n t i a l . 
Evaluation of oncological treatments should be 
considered only for disseminated bilateral lung 
lesions. Adenocarcinoma with ground-glass 
opacities (GGO) present rare incidence of ALK 
translocations. Different studies have evaluated 
the incidence of EGFR mutations and GGO, 
confirming that there is no significant association 
between GGO and EGFR mutations (10-16);
(IV) Pneumonic-type of lung adenocarcinoma. Staging 
and treatment evaluation for this particular type 
of lung cancer should follow the usual guidelines 
for the treatment of NSCLC. In patients with 
this histopathological diagnosis , EGFR mutation 
analysis should be considered as mandatory. Indeed, 
EGFR mutations appear to be significantly high in 
this histological subtype (17).
Conclusions
The new proposal for revision of the classification of lung 
cancers with multiple pulmonary sites, according to four 
different categories, should help in choosing the proper 
treatment for patients with multiple tumor nodules. However, 
some ambiguities in differentiating same or different entities 
still exist, especially in the first two categories, in case 
histological examination cannot be performed.
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